|Bid||40.25 x 800|
|Ask||0.00 x 900|
|Day's Range||41.50 - 43.95|
|52 Week Range||20.03 - 54.97|
|Beta (5Y Monthly)||1.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 24, 2021 - Mar. 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||63.33|
The latest analyst coverage could presage a bad day for REGENXBIO Inc. ( NASDAQ:RGNX ), with the analysts making...
REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy
These three small-cap stocks all turned a profit last quarter and present ample growth potential at bargain prices.